Fresenius Kabi Launches Tyenne, Europe’s First Tocilizumab Biosimilar for Inflammatory Diseases and COVID-19
Shots:
- Fresenius Kabi has launched Tyenne, first tocilizumab biosimilar, in the EU to treat inflammatory and immune diseases, incl. rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis, cytokine release syndrome (CRS) and COVID-19
- Tyenne offers flexible administration options with SC (prefilled syringe and autoinjector) and IV (vials) delivery methods, contributing to patient access and healthcare system sustainability
- KabiCare, Fresenius Kabi's patient support program, is accessible to patients and HCPs in the EU from the launch, emphasizing their dedication to providing comprehensive assistance
Ref: Fresenius | Image: Fresenius
Related News:- Fresenius Kabi’s Tyenne (biosimilar, tocilizumab) Receives EC’s Approval for Multiple Inflammatory and Immune Mediated Conditions
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
